Evidence map›Paper›PMID 30173955›Full record

ArticleCell host & microbe2018

Capsid-CPSF6 Interaction Licenses Nuclear HIV-1 Trafficking to Sites of Viral DNA Integration.

Vasudevan Achuthan, Jill M Perreira, Gregory A Sowd, Maritza Puray-Chavez, William M McDougall, Adriana Paulucci-Holthauzen, Xiaolin Wu, Hind J Fadel, Eric M Poeschla, Asha S Multani and 4 more

Abstract read
In one paragraph

Article in Cell host & microbe, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 158 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
158citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

158 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. HIV-1 capsid interactions with Nuclear Pore Complex components support nuclear entry via affinity gradient.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  4. Review
  5. Article
  6. MX2 Mediates Collapse of the HIV-1 Capsid.bioRxiv : the preprint server for biology · 2026
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. bioRxiv : the preprint server for biology · 2026
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

98 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Vasudevan AchuthanDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Jill M PerreiraDepartment of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA 01655, USA.
Gregory A SowdDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Maritza Puray-ChavezDepartment of Molecular Microbiology & Immunology, University of Missouri School of Medicine, Columbia, MO 65212, USA.
William M McDougallDepartment of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA 01655, USA.
Adriana Paulucci-HolthauzenDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Xiaolin WuLeidos Biomedical Research, Inc., Frederick, MD 21702, USA.
Hind J FadelDivision of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Eric M PoeschlaDivision of Infectious Diseases, University of Colorado Denver School of Medicine, Aurora, CO 80045, USA.
Asha S MultaniDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Stephen H HughesHIV Dynamics and Replication Program, National Cancer Institute, Frederick, MD 21702, USA.
Stefan G SarafianosDepartment of Molecular Microbiology & Immunology, University of Missouri School of Medicine, Columbia, MO 65212, USA.
Abraham L BrassDepartment of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA 01655, USA; Gastroenterology Division, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA. Electronic address: abraham.brass@umassmed.edu.
Alan N EngelmanDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA. Electronic address: alan_engelman@dfci.harvard.edu.

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4M
IntegraseZIABC011426 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HUGHES, STEPHEN H · 2012 to 2022
$14.0M
Nuclear Localization of HIV-1 Preintegration ComplexesR01AI052014 · NIAID · DANA-FARBER CANCER INSTITUTE · PI ENGELMAN, ALAN N. · 2003 to 2025
$11.4M
MOLECULAR BASIS OF VIRAL INFECTIVITYT32AI007245 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Aaron Gregory Schmidt · 1985 to 2026
$11.3M
Biochemical Mechanism of HIV DNA IntegrationR37AI039394 · NIAID · DANA-FARBER CANCER INST · PI Alan N. Engelman · 2010 to 2026
$10.2M
LEDGF/p7 and HIV IntegrationR01AI077344 · NIAID · UNIVERSITY OF COLORADO DENVER · PI POESCHLA, ERIC M. · 2008 to 2018
$4.1M
Novel Approaches to Innate Immunity Against HIV-1 and Other Co-infection VirusesDP1DA043915 · NIDA · UNIVERSITY OF COLORADO DENVER · PI POESCHLA, ERIC M. · 2017 to 2021
$3.9M
Engineering an HIV-resistant immune system for HIV cureK08AI122838 · NIAID · MAYO CLINIC ROCHESTER · PI FADEL, HIND JAWDAT · 2016 to 2020
$955k
NIAID NIH HHS K08 AI122838NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI052014NIAID NIH HHS R01 AI077344NIAID NIH HHS R37 AI039394NIAID NIH HHS T32 AI007245NIDA NIH HHS DP1 DA043915
6 · The paper itself

Abstract

HIV-1 integration into the host genome favors actively transcribed genes. Prior work indicated that the nuclear periphery provides the architectural basis for integration site selection, with viral capsid-binding host cofactor CPSF6 and viral integrase-binding cofactor LEDGF/p75 contributing to selection of individual sites. Here, by investigating the early phase of infection, we determine that HIV-1 traffics throughout the nucleus for integration. CPSF6-capsid interactions allow the virus to bypass peripheral heterochromatin and penetrate the nuclear structure for integration. Loss of interaction with CPSF6 dramatically alters virus localization toward the nuclear periphery and integration into transcriptionally repressed lamina-associated heterochromatin, while loss of LEDGF/p75 does not significantly affect intranuclear HIV-1 localization. Thus, CPSF6 serves as a master regulator of HIV-1 intranuclear localization by trafficking viral preintegration complexes away from heterochromatin at the periphery toward gene-dense chromosomal regions within the nuclear interior.

Indexed as

Virus IntegrationCapsidCell NucleusDNA, ViralHIV-1HIV InfectionsHost-Pathogen InteractionsHumansIntercellular Signaling Peptides and ProteinsmRNA Cleavage and Polyadenylation FactorsProtein BindingVirus Replicationcleavage factor Im, humanDNA, ViralIntercellular Signaling Peptides and Proteinslens epithelium-derived growth factormRNA Cleavage and Polyadenylation FactorsCPSF6HIV capsidHIV integraseHIV integrationHIV traffickinglamina-associated domainLEDGF/p75nuclear trafficking

Identifiers

PMID30173955
PMCPMC6368089

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.